Haemonetics Corporation (NYSE:HAE) Shares Bought by Peregrine Capital Management LLC

Peregrine Capital Management LLC boosted its position in shares of Haemonetics Corporation (NYSE:HAE - Free Report) by 13.8% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 161,406 shares of the medical instruments supplier's stock after acquiring an additional 19,603 shares during the period. Peregrine Capital Management LLC owned about 0.32% of Haemonetics worth $10,257,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the company. TD Waterhouse Canada Inc. acquired a new stake in shares of Haemonetics during the 4th quarter worth about $25,000. Covestor Ltd increased its stake in Haemonetics by 146.8% in the fourth quarter. Covestor Ltd now owns 738 shares of the medical instruments supplier's stock valued at $58,000 after purchasing an additional 439 shares during the last quarter. Whittier Trust Co. acquired a new stake in Haemonetics during the fourth quarter worth approximately $62,000. Parkside Financial Bank & Trust lifted its position in shares of Haemonetics by 25.6% during the 4th quarter. Parkside Financial Bank & Trust now owns 1,176 shares of the medical instruments supplier's stock worth $92,000 after buying an additional 240 shares during the last quarter. Finally, AlphaQuest LLC boosted its holdings in shares of Haemonetics by 36,520.0% in the 4th quarter. AlphaQuest LLC now owns 1,831 shares of the medical instruments supplier's stock valued at $143,000 after buying an additional 1,826 shares in the last quarter. 99.67% of the stock is owned by hedge funds and other institutional investors.

Haemonetics Stock Performance

NYSE HAE traded up $0.61 during trading hours on Thursday, hitting $76.85. 249,556 shares of the stock were exchanged, compared to its average volume of 669,827. The company has a quick ratio of 0.99, a current ratio of 1.62 and a debt-to-equity ratio of 1.12. The company has a market cap of $3.69 billion, a price-to-earnings ratio of 23.22, a price-to-earnings-growth ratio of 1.24 and a beta of 0.39. Haemonetics Corporation has a 12-month low of $55.30 and a 12-month high of $94.99. The stock has a 50-day moving average of $68.82 and a 200 day moving average of $68.14.

Haemonetics (NYSE:HAE - Get Free Report) last issued its earnings results on Thursday, May 8th. The medical instruments supplier reported $1.24 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.22 by $0.02. Haemonetics had a return on equity of 26.37% and a net margin of 12.32%. The business had revenue of $330.60 million during the quarter, compared to the consensus estimate of $329.38 million. During the same period in the prior year, the business posted $0.90 EPS. The company's revenue for the quarter was down 3.5% on a year-over-year basis. As a group, equities research analysts forecast that Haemonetics Corporation will post 4.55 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on HAE shares. JMP Securities reiterated a "market outperform" rating and set a $100.00 price target on shares of Haemonetics in a research note on Tuesday, May 20th. Baird R W upgraded Haemonetics to a "strong-buy" rating in a research report on Wednesday, June 25th. Needham & Company LLC decreased their target price on Haemonetics from $104.00 to $84.00 and set a "buy" rating for the company in a research report on Thursday, May 8th. Robert W. Baird began coverage on Haemonetics in a research report on Thursday, June 26th. They set an "outperform" rating and a $87.00 price target on the stock. Finally, Wall Street Zen cut Haemonetics from a "buy" rating to a "hold" rating in a research note on Tuesday, May 13th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, seven have given a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $96.80.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.